Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bernard Osher Foundation | UNKNOWN |
| National Institutes of Health (NIH) | NIH |
Not provided
Not provided
Not provided
Not provided
This study is looking at whether Pilates-based exercise can help with hypermobility-related symptoms, like pain.
In this study, investigators are looking at whether 6 weeks of Pilates-based exercise led by a licensed physical therapist can help with hypermobility-related symptoms, like pain. Pilates is a gentle mind-body exercise with an emphasis on muscular control, postural awareness, and breathing that may be particularly well-suited for managing hypermobility. Exercises are mostly floor-based and focus on developing muscular strength and stability which may improve pain and symptom management.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pilates | Experimental | 6 weeks of once weekly in-person Pilates-based exercise classes |
|
| Enhanced Usual Care | Active Comparator | 6 weeks of once weekly educational seminars pertaining to hypermobility symptom management |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pilates | Behavioral | Pilates is a gentle mind-body exercise with an emphasis on muscular control, postural awareness, and breathing that may be particularly well-suited for managing hypermobility. Exercises are mostly floor-based and focus on developing muscular strength and stability which may improve pain and symptom management |
| Measure | Description | Time Frame |
|---|---|---|
| Intervention Feasibility | Recruitment, Retention, Attendance | Enrollment to end of intervention (week 6) and follow-up (week 12) |
| Acceptability | Treatment Helpfulness Questionnaire (THQ): The THQ is a single-item measure that evaluates the perception of helpfulness of an intervention. Participants will be asked to rate the helpfulness of the intervention to which they are randomized on a scale of -5 (extremely harmful) to 5 (extremely helpful) with 0 indicating "neutral." | Enrollment to end of intervention (week 6) |
| Measure | Description | Time Frame |
|---|---|---|
| Pain intensity | The Patient Reported Outcomes Measurement Information System Profile (PROMIS-29) will be used to assess pain intensity. Scores range from 8-40 with higher scores indicating a greater presence of the corresponding construct. | Baseline, week 6 and week 12 |
| Pain interference |
| Measure | Description | Time Frame |
|---|---|---|
| Pain Sensitivity | Pain sensitivity will be assessed using a Quantitative Sensory Testing (QST) battery. The QST assessment will include responses to innocuous stimuli, mechanical pain sensitivity, heat sensitivity, conditioned pain modulation, and temporal summation of pain (a measure of central sensitizability). | Baseline testing |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Stephanie Voss, PhD | Contact | 6177329181 | svoss2@bwh.harvard.edu |
| Name | Affiliation | Role |
|---|---|---|
| Samantha Meints, PhD | Brigham and Women's Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Brigham and Women's Hospital | Recruiting | Chestnut Hill | Massachusetts | 01467 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D004535 | Ehlers-Danlos Syndrome |
| C536196 | Ehlers-Danlos syndrome type 3 |
| D010146 | Pain |
| ID | Term |
|---|---|
| D020141 | Hemostatic Disorders |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D006474 | Hemorrhagic Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D026241 | Exercise Movement Techniques |
| D004522 | Educational Status |
| ID | Term |
|---|---|
| D026741 | Physical Therapy Modalities |
| D013812 | Therapeutics |
| D012959 | Socioeconomic Factors |
| D011154 | Population Characteristics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Education | Behavioral | Educational seminars pertaining to hypermobility symptom management |
|
The Patient Reported Outcomes Measurement Information System Profile (PROMIS-29) will be used to assess pain interference. Scores range from 8-40 with higher scores indicating a greater presence of the corresponding construct. |
| Baseline, week 6 and week 12 |
| Bristol Questionnaire | The Bristol Impact of Hypermobility Questionnaire will be used to assess the self-reported functional impact of joint hypermobility. Higher scores indicate more severe functional impact | Baseline, week 6 and week 12 |
| WPI | The Widespread Pain Inventory (WPI) will be used to assess the widespreadness of body pain. Scores range from 0-19 with higher scores indicating more widespread pain. | Baseline, week 6 and week 12 |
| PCS | The Pain Catastrophizing Scale (PCS) will be used to assess pain-related rumination, magnification, and helplessness in response to pain. Scores range from 0-52 with higher scores indicating more pain catastrophizing. | Baseline, week 6 and week 12 |
| MAIA-2 | The Multidimensional Assessment of Interoceptive Awareness-2 (MAIA-2) will be used to assess 8 domains pertaining to beliefs about the body and tendencies to be internally focused, including noticing, not distracting, not worrying, attention regulation, emotional awareness, body listening and trusting. Scores range from 0-5 with higher scores indicating higher interoceptive sensibility. | Baseline, week 6 and week 12 |
| TSK | The Tampa Scale of Kinesiophobia (TSK) will be used to assess fear of movement. Scores range from 17-68 with higher scores indicating more fear of movement. | Baseline, week 6 and week 12 |
| SHS | The Sensory Hypersensitivity Scale (SHS) will be used to assess multisensory sensitivity to items related to sensitivity to light, heat, cold, allergies, pain, smell, hearing, taste, and touch. Higher scores indicate more multisensory sensitivity. The scale will be modified to include an additional rating of bothersomeness from 1 (Not bothersome at all) to 5 (Extremely bothersome) for each of the original scale items to evaluate multisensory bothersomeness | Baseline, week 6 and week 12 |
| Overall physical and mental health | The Patient Reported Outcomes Measurement Information System Profile (PROMIS-29) will be used to assess overall physical and mental health, with subscales including physical function, anxiety, depression, fatigue, social participation, and sleep disturbance. Scores range from 8-40 with higher scores indicating a greater degree of the corresponding construct | Baseline, week 6 and week 12 |
| Heartrate Variability | resting HRV | Enrollment to end of intervention (week 6) and follow-up (week 12) |
| Functional mobility | Functional mobility will be assessed using the Timed Up and Go (TUG) test | Enrollment to end of intervention (week 6) and follow-up (week 12) |
| Functional endurance | Functional endurance will be measured with the 2-minute walk test (2MWT) | Enrollment to end of intervention (week 6) and follow-up (week 12) |
| D006402 |
| Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D012868 | Skin Abnormalities |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D012873 | Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D003095 | Collagen Diseases |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012871 | Skin Diseases |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |